Phase 3 RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma
Summary
NIH registered a Phase 3 randomized controlled clinical trial (NCT07540390) evaluating GAPP induction therapy combined with concurrent chemoradiotherapy and toripalimab maintenance for high-risk locoregionally advanced nasopharyngeal carcinoma (Stage III, AJCC 9th edition). The experimental arm combines PD-1 antibody (toripalimab), anlotinib, cisplatin, gemcitabine, and radiation, while the control arm uses the current guideline-recommended GPP induction chemotherapy regimen. The multicenter open-label study aims to generate evidence-based data on the efficacy and safety of this novel combination.
What changed
NIH published a clinical trial registration for a multicenter, open-label, randomized Phase 3 study (NCT07540390) enrolling patients with high-risk locoregionally advanced nasopharyngeal carcinoma (Stage III, AJCC 9th edition). The trial evaluates an experimental regimen combining GAPP induction chemotherapy with PD-1 inhibitor toripalimab, tyrosine kinase inhibitor anlotinib, cisplatin, gemcitabine, and radiation therapy against the current standard-of-care GPP induction followed by concurrent chemoradiotherapy and toripalimab maintenance. The study includes approximately 306 participants and uses an event-driven analysis design.
Pharmaceutical sponsors developing toripalimab or anlotinib-related oncology combinations should monitor this trial for potential label-expansion implications. Clinical investigators at participating centers must ensure IRB approval and IND compliance. The trial's comparative design against an established standard-of-care may inform future FDA labeling decisions and payer coverage policies for nasopharyngeal carcinoma treatment.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
Phase 3 NCT07540390 Kind: PHASE3 Apr 20, 2026
Abstract
The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk locoregionally advanced nasopharyngeal carcinoma (stage III, AJCC 9th edition). The aim is to obtain high-level, high-quality evidence-based data to clarify the efficacy and safety of combining chemoradiotherapy with PD-1 antibody and anlotinib, thereby providing a new treatment strategy to improve the prognosis of patients with high-risk locoregionally advanced nasopharyngeal carcinoma. In this study, GPP induction chemotherapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy is selected as the control group. This regimen is currently the standard treatment recommended by guidelines for high-risk locoregionally advanced nasopharyngeal carcinoma, with well-established efficacy and broad clinical application. It provides a reliable benchmark for comparing the efficacy and safety of the experimental group, meets ethical requirements, and has mature clinical operational procedures.
Conditions: Nasopharyngeal Carcinoma
Interventions: Toripalimab, Anlotinib, Cisplatin, Gemcitabine, radiation
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.